Chemotherapy-Induced Neutropenia Treatment Market Size & Share 2024 to 2032

Chemotherapy-Induced Neutropenia Treatment Market Size

Chemotherapy-Induced Neutropenia Treatment Market size was valued at USD 584.2 million in 2023 and is expected to exhibit growth at a CAGR of 3.7% from 2024 – 2032. High market growth can be attributed to the ongoing advancements in treatment options, growing use of chemotherapy, increase in the cancer incidences, and expanding healthcare expenditure in developing countries, among other contributing factors.

Moreover, the rising prevalence of cancer globally is a significant driver for the chemotherapy-induced neutropenia (CIN) treatment market. Chemotherapy is a common treatment modality for various types of cancers and neutropenia is a common side effect of chemotherapy. For instance, according to American Cancer Society, Inc. in 2023, more than 1.9 million new cancer cases were diagnosed in the U.S. As the incidence of cancer continues to increase, the demand for effective CIN treatments also rises.
 

Furthermore, advancements in cancer diagnosis and treatment have led to an increased utilization of chemotherapy in cancer management. Chemotherapy is employed as a curative or palliative treatment, either as a standalone therapy or in combination with surgery, radiation therapy, or targeted therapy. The expanding use of chemotherapy across various cancer types and stages contributes to a higher incidence of CIN, driving the demand for effective treatments to manage or prevent neutropenia-related complications.
 

Chemotherapy-induced neutropenia treatment refers to the medical interventions and supportive care measures aimed at managing or preventing neutropenia, a common side effect of chemotherapy. Neutropenia is characterized by a decrease in the number of neutrophils, a type of white blood cell that plays a crucial role in the body's immune response against infections.
 

Chemotherapy-Induced Neutropenia Treatment Market Trends

The market is experiencing several notable trends that are shaping its growth and development. Factors such as growing demand for biosimilar, increasing focus on supportive care, rise in stem cell therapies, and surging need for integrated digital health solutions, among other factors are propelling the industry growth.
 

• Biosimilar versions of colony-stimulating factors (CSFs), such as filgrastim and pegfilgrastim, are gaining traction in the market. These biosimilars offer comparable efficacy and safety profiles to their originator drugs but at potentially lower costs. Thus, increased adoption of biosimilars enhances competition in the market, potentially reducing treatment costs and expanding access to CIN therapies.
   
• Moreover, advancements in molecular diagnostics and genomic profiling enable personalized treatment approaches tailored to individual patient characteristics, such as genetic predisposition and cancer type. Personalized medicine optimizes treatment efficacy and safety by targeting therapies to patients most likely to benefit, minimizing adverse effects and improving overall outcomes.
   

Chemotherapy-Induced Neutropenia Treatment Market Analysis

Based on treatment type, the market is segmented into granulocyte colony-stimulating factor therapy, antibiotics, granulocyte transfusion, antifungals, and other treatment types. The granulocyte colony-stimulating factor therapy segment dominated the market in 2023 with a revenue of USD 328.5 million.
 

• G-CSF therapy is effective in preventing and managing neutropenia, a common side effect of chemotherapy characterized by a decrease in neutrophil count. By stimulating neutrophil production, G-CSF therapy helps maintain adequate levels of neutrophils, reducing the risk of severe neutropenia and associated complications, such as infections and treatment delays.
   
• Moreover, neutropenia-related complications, such as febrile neutropenia, can lead to treatment interruptions, dose reductions, and hospitalizations, impacting patient quality of life and treatment adherence. G-CSF therapy reduces the incidence of neutropenia-related complications, allowing patients to tolerate chemotherapy better and adhere to treatment regimens. This leads to improved patient comfort, satisfaction, and overall treatment outcomes, thus leading to the segmental growth.

Learn more about the key segments shaping this market

Download Free PDF

The chemotherapy-induced neutropenia treatment market based on drug type is classified into branded and biosimilars. The branded segment dominated the market in 2023 with a market share of 61%.
 

• Branded drugs in the CIN treatment market typically undergo extensive clinical trials to demonstrate their efficacy and safety profiles. These trials generate robust data supporting the therapeutic benefits and safety of branded drugs. Healthcare providers and patients often place greater trust in branded drugs with well-established efficacy and safety profiles. The perceived reliability and effectiveness of branded drugs drive their preference and demand in the CIN treatment market.
   
• Additionally, branded drugs typically have patent protection, which grants the pharmaceutical company exclusive rights to manufacture and sell the drug for a certain period (usually 20 years), During this time, generic versions of the drug cannot enter the market, allowing the branded drug’s company to maintain a dominance and charge higher prices. This is anticipated to boost the segmental growth in the market.
   

Based on route of administration, the chemotherapy-induced neutropenia treatment market is classified into parenteral and oral. The parenteral segment dominated the market and is expected to grow at a pace of 3.8% CAGR between 2024 – 2032.
 

• Parenteral therapies, including injectable medications such as granulocyte colony-stimulating factors (G-CSFs) like filgrastim and pegfilgrastim, are highly effective in stimulating the production of neutrophils in the bone marrow. They rapidly increase neutrophil counts, reducing the duration and severity of neutropenia and its associated complications. The quick onset of action of parenteral therapies is crucial in managing CIN and making them indispensable in chemotherapy regimens.
   
• Furthermore, CIN increases the risk of developing severe infections, which can lead to hospitalization, treatment interruptions, and compromised treatment outcomes. Parenteral therapies help prevent infections by boosting neutrophil counts, thereby reducing the likelihood of febrile neutropenia and its associated complications. The ability of parenteral therapies to mitigate the risk of infections improves patient safety, treatment adherence, and overall treatment efficacy.
   

Based on distribution channel, the chemotherapy-induced neutropenia treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2023 and is anticipated to reach USD 444.9 million by 2032.
 

• Hospital pharmacies serve as centralized hubs for medication distribution within healthcare facilities, including chemotherapy drugs and supportive care medications for managing CIN. The presence of a well-stocked hospital pharmacy ensures timely access to CIN treatments for patients undergoing chemotherapy.
   
• Moreover, it provide comprehensive medication management services for patients receiving chemotherapy, including dose calculation, drug dispensing, and medication counseling. Pharmacists collaborate with healthcare teams to optimize CIN treatment regimens, ensure medication adherence, and monitor for adverse drug reactions. This is anticipated to boost the segmental growth in the market.

North America chemotherapy-induced neutropenia treatment market accounted for USD 212.7 million market revenue in 2023 and is anticipated to grow at CAGR of 3.5% between 2024 – 2032 period.
 

• North America has a relatively high incidence of cancer, with millions of new cases diagnosed each year. Chemotherapy is a common treatment modality for various cancers, contributing to the prevalence of CIN in the region. The widespread use of chemotherapy drives demand for CIN treatments in the region.
   
• Furthermore, the region boasts advanced healthcare infrastructure, including well-equipped hospitals, specialized cancer centers, and research institutions. The presence of state-of-the-art facilities and expertise in oncology supports the diagnosis, treatment, and management of CIN, driving market demand for innovative therapies and supportive care interventions.
   

The U.S. held a dominant position in the chemotherapy-induced neutropenia treatment market, with a revenue of USD 196.9 million in 2023.
 

• Hematologic malignancies, such as leukemia, lymphoma, and multiple myeloma, are prevalent in the U.S. and often require intensive chemotherapy regimens. For instance, according to the Leukemia & Lymphoma Society (LLS), around 184,720 individuals in the U.S. were diagnosed with leukemia, lymphoma, or myeloma in the year 2023.
   
• Patients with hematologic cancers are at increased risk of developing severe neutropenia and infectious complications, driving demand for effective CIN treatments to support chemotherapy delivery and optimize patient outcomes.
   

Germany chemotherapy-induced neutropenia treatment market is projected to grow remarkably in the coming years.
 

• Germany has a robust pharmaceutical industry known for its research and development (R&D) capabilities, manufacturing expertise, and regulatory compliance. Domestic and multinational pharmaceutical companies invest in developing and commercializing CIN treatments tailored to the needs of German patients. This strong pharmaceutical sector fosters innovation and competition in the market.
   
• Furthermore, the country is renowned for its excellence in biomedical research and academic institutions. Leading universities, research organizations, and cancer centers conduct cutting-edge research on cancer and supportive care interventions, including CIN treatment. Collaborative research efforts drive innovation and the development of novel therapies in the German market.
   

Japan holds a dominant position in the Asia Pacific chemotherapy-induced neutropenia treatment market.
 

• Japan is a leader in healthcare technology and innovation, with a strong emphasis on the development of advanced medical devices, diagnostic tools, and treatment modalities. Technological advancements enhance the diagnosis, monitoring, and management of CIN, leading to improved treatment outcomes and patient care.
   
• Moreover, it has one of the world's oldest populations, with a significant proportion of elderly individuals who are at higher risk of cancer and chemotherapy-related complications, including CIN. The aging population drives demand for CIN treatments tailored to the needs of older adults, including supportive care interventions to manage treatment-related side effects.
   

Chemotherapy-Induced Neutropenia Treatment Market Share

The market encompasses a range of therapeutic interventions aimed at preventing and managing neutropenia, a common complication of chemotherapy. The market is characterized by the presence of established pharmaceutical companies offering innovative treatment options and biosimilar alternatives, along with a growing focus on personalized medicine approaches and targeted therapies. With advancements in oncology research, and expanding patient access to care, the CIN treatment market continues to evolve, catering to the diverse needs of patients undergoing chemotherapy worldwide.
 

Chemotherapy-Induced Neutropenia Treatment Companies

Prominent players operating in the chemotherapy-induced neutropenia treatment industry include:

• Amgen Inc.
• BeyondSpring Inc.
• Biocon Biologics Inc.
• Cellerant Therapeutics
• Coherus BioSciences, Inc.
• Evive Biotech
• Kyowa Kirin Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Spectrum Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
   

Chemotherapy-Induced Neutropenia Treatment Industry News:

• In March 2023, Coherus BioSciences, Inc. announced that the U.S. Food and Drug Administration ("FDA") has approved UDENYCA (pegfilgrastim-cbqv), a biosimilar pegfilgrastim administered the day after chemotherapy to reduce the incidence of infection as indicated by febrile neutropenia. The UDENYCA autoinjector, with its simplified, user-friendly design, offers convenience in both office and home care settings.
   
• In November 2023, Evive Biotech (Evive) announced that the U.S. Food and Drug Administration (FDA) has approved Ryzneuta (Efbemalenograstim alfa), a unique long-acting Granulocyte colony-stimulating factor (G-CSF) indicated to reduce the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Ryzneuta promotes neutrophil proliferation, differentiation, and release, enhancing cancer patients' immunological function and reducing the negative effects of chemotherapy-induced neutropenia.
   

The chemotherapy-induced neutropenia treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Granulocyte colony-stimulating factor therapy
• Antibiotics
• Granulocyte transfusion
• Antifungals
• Other treatment types

Market, By Drug Type

• Branded
• Biosimilars

Market, By Route of administration

• Parenteral
• Oral

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa